Cyclacel
Investors & Media

News

All Releases
View Summary Cyclacel's CYC065 Demonstrates Promising Activity in MYCN-Addicted Neuroblastoma in Preclinical Data Presented at Childhood Cancer 2016
Sep 6, 2016
PDF 56.4 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals Reports 2nd Quarter 2016 Financial Results
Aug 10, 2016
PDF 28.6 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals to Release Second Quarter 2016 Financial Results
Aug 3, 2016
PDF 12.7 KB Add to Briefcase
View Summary Cyclacel's CYC065 Demonstrates Promising Activity in Uterine Serous Carcinoma in Preclinical Data Published by Independent Academic Researchers
Aug 2, 2016
PDF 17.0 KB Add to Briefcase
View Summary Cyclacel Regains Compliance With Nasdaq Continued Listing Requirements
Jun 16, 2016
PDF 13.4 KB Add to Briefcase
View Summary Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine Combination in Patients With Solid Tumors at ASCO
Jun 6, 2016
PDF 22.8 KB Add to Briefcase
View Summary Cyclacel Announces Reverse Stock Split
May 27, 2016
PDF 14.8 KB Add to Briefcase
View Summary Cyclacel's Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
May 19, 2016
PDF 14.5 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results
May 11, 2016
PDF 28.3 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals to Release First Quarter 2016 Financial Results
May 4, 2016
PDF 13.9 KB Add to Briefcase
View Summary Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors
Apr 18, 2016
PDF 285.3 KB Add to Briefcase
View Summary Cyclacel Announces Receipt of Nasdaq Extension
Apr 11, 2016
PDF 13.5 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results
Mar 24, 2016
PDF 31.3 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2015 Financial Results
Mar 17, 2016
PDF 13.4 KB Add to Briefcase
View Summary Cyclacel Announces Receipt of Nasdaq Staff Determination; Company to Request Hearing
Feb 5, 2016
PDF 13.0 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference
Feb 2, 2016
PDF 13.1 KB Add to Briefcase
View Summary Cyclacel Reviews 2015 Achievements and Announces Key Business Objectives for 2016
Jan 11, 2016
PDF 20.9 KB Add to Briefcase
View Summary Molecular Basis For Development of Cyclacel's CYC065 CDK2/9 Inhibitor In Triple-Negative Breast Cancer Presented At San Antonio Breast Cancer Symposium
Dec 14, 2015
PDF 15.1 KB Add to Briefcase
View Summary CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models
Nov 23, 2015
PDF 56.3 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals Reports Third Quarter 2015 Financial Results
Nov 12, 2015
PDF 29.1 KB Add to Briefcase
Showing 21-40 of 351 Page: 1 2 3 4 5 6 ... 18  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase
Investors & Media